Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aptinyx
With
Worldwide Clinical Trials
This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with fibromyalgia.
This 13- to 16-week study will include a 1- to 4-week Screening Period followed by a 12-week double-blind, randomized, placebo-controlled Treatment Period.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent
Subject has a history of fibromyalgia that was diagnosed \>1 year prior to screening and reports at least moderate pain over the last week
Stable protocol allowed medication and other therapies during the study
Agrees to use highly effective birth control during the study
Has not participated in an interventional study for at least 30 days and agrees not to participate in another interventional study during the study
You may not be if
Pain due to other conditions or diseases that would complicate participation in the study or pain reporting
Current or historical serious medical conditions
Prior participation in NYX-2925 clinical trial
Clareo Health | Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
